Tumour cell migration and adhesion constitute essential features of metastasis. G-protein coupled receptor 55 (GPR55), a lysophospholipid receptor, has been shown to play an important role in carcinogenesis. Here, we investigated the involvement of GPR55 in migration and metastasis of colon cancer cells.
Tables of Links Introduction
The G-protein coupled receptor 55 (GPR55), a lysophosphatidylinositol (LPI) receptor, has recently emerged as a potential novel target in antitumour treatment because of its involvement in several hallmarks of cancer, such as proliferation, invasion and angiogenesis (Henstridge et al., 2011; Ross, 2011) . GPR55 was originally described as a receptor responsive to natural, synthetic and endogenous cannabinoids like anandamide (Ryberg et al., 2007) , however, the only consistent data eventually pointed to LPI as its true endogenous ligand (Henstridge et al., 2009; Oka et al., 2009) . High levels of GPR55 have been detected in the CNS, spleen and the gastrointestinal tract (Henstridge et al., 2011) . It has been also identified in several types of cancer cells, such as glioma, melanoma, breast and pancreatic cancer cells (Ford et al., 2010; Andradas et al., 2011; Piñeiro et al., 2011; Pérez-Gómez et al., 2012) . Unlike cannabinoid receptors, GPR55 signals through G α12/13 and G q proteins initiating excitatory rather than inhibitory effects (Lauckner et al., 2008) . In line with this concept, GPR55 has been implicated in the development of neuropathic and inflammatory pain through modulation of pro-inflammatory cytokines (Staton et al., 2008) . Structurally, GPR55 is related to several cancer-relevant GPCRs including GPR35, GPR92 and GPR23 (Fredriksson et al., 2003) . Because signalling pathways initiated by G α12/13 subunits contribute to cancer-related mechanisms such as proliferation, migration and invasion (Juneja and Casey, 2009 ), a role for GPR55 in the development of cancer has been suspected. Indeed, overexpression of GPR55 enhances whereas silencing of GPR55 reduces viability of breast, glioma and pancreatic cancer cells . The receptor is up-regulated in tumours of human pancreatic and skin cancers and positively correlates with tumour aggressiveness in skin and oral squamous cell carcinomas and glioblastoma Pérez-Gómez et al., 2012) . A recent study using a model of skin cancer in GPR55 knock-out mice revealed that proliferation of epidermal cells was reduced (Pérez-Gómez et al., 2012) . It is most likely that GPR55-mediated proliferation of cancer cells involves MAPK pathways Piñeiro et al., 2011) . Contrary to these studies, antiproliferative effects of GPR55 have been described in cholangiocarcinoma cells (Huang et al., 2011) .
Little is known about the role of GPR55 in the metastatic behaviour of cancer cells, and colon cancer in particular. GPCRs play a central role in metastasis owing to their ability to regulate cell migration (Dorsam and Gutkind, 2007) . Also, Ca 2+ homeostasis is altered in metastatic cancer cells (Prevarskaya et al., 2011) . Previous studies indicate a role for GPR55 in the migration of endothelial, skin and breast cancer cells (Ford et al., 2010; Zhang et al., 2010; Pérez-Gómez et al., 2012) . These studies and other findings on the cellular pathways initiated by LPI point to a possible role for the GPR55-LPI axis in colon cancer cell migration and invasion. Activation of GPR55 by LPI initiates downstream events crucial for the migration of cancer cells, such as Ca 2+ mobilization (Henstridge et al., 2009 ), ERK1/2 phosphorylation Piñeiro et al., 2011) and activation of serum response element (Kargl et al., 2012) . In addition, LPI also activates migration-promoting signalling protein RhoA in GPR55-HEK293 cells (Henstridge et al., 2009 ) and human neutrophils . To investigate the role of GPR55 and LPI in the migration and possible metastasis of colon cancer cells, we used the highly metastatic colon cancer cell line HCT116 (Rajput et al., 2008) to demonstrate the involvement of GPR55 in colon cancer. For pharmacological blockade, we used the selective GPR55 antagonist CID16020046 (Kargl et al., 2013a) and cannabidiol, which may act as a GPR55 inhibitor (Ryberg et al., 2007; Anavi-Goffer et al., 2012) . Because cannabidiol has been shown to use multiple mechanisms for prevention of experimental carcinogenesis (Aviello et al., 2012) , we were interested whether cannabidiol would exert its anticarcinogenic effects in our experiments via GPR55. Our in vitro assays demonstrated that GPR55 is involved in adhesion and migration of colon cancer cells. Using an in vivo model of tumour cell metastasis, we show that after intrasplenic injection of HCT116-CMVp-Luc colon cancer cells, the arrest of cells is reduced in liver tissue of mice treated with CID16020046 or cannabidiol. We also detected increased LPI (18:0) content in the blood of colon cancer patients when compared with healthy donors. This study provides evidence that GPR55 is involved in the metastatic behaviour of colon cancer cells. 
LIGANDS

PCR
RNA isolation, reverse transcription PCR (RT-PCR) and qPCR were performed as previously described (Kargl et al., 2013b) using the following primers for GPR55: (forward: 5′-CCT CCCATTCAAGATGGTCC-3′; reverse: 5′-GACGCTTCCGTA CATGCTGA-3′) and GAPDH: (forward: 5′-ATGGGGAAGGTG AAGGTCG-3′; reverse: 5′-GGGGTCATTGATG-GCAACAATA-3′). Data from real-time PCR were analysed using the 2 ÀΔΔct method or calculated by using a standard curve. A pcDNA3.1 plasmid encoding the GPR55 gene served for standard curve calculation, and the absolute mRNA copy number was assessed. 
Adhesion assay
Cell viability assay
The number of viable cells was determined using the Cell Titer 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) as previously described (Kargl et al., 2013b) .
F-actin staining
HCT116 cells were grown on poly-D-lysine-coated slides and starved for 4 h. Cells were pretreated with DMSO, 1 μM cannabidiol or CID16020046 for 10 min and stimulated with 1 μM LPI for 15 min. Subsequently, cells were fixed, permeabilized, blocked and incubated with the Texas Red-conjugated phalloidin. Cells were wet-mounted onto microscopy slides with DAPI mounting medium (Vectashield ®; Vector Laboratories, Inc., Burlingame, CA, USA).
Spot assays
The assay was carried out according to Wiggins and Rappoport (2010) 
Transwell migration assay
Migration assays were performed in 24-well Transwell plates with 8 μm membrane inserts (Corning Inc., Lowell, MA, USA). Cells were starved in Opti-MEM and then incubated with GPR55 inhibitor CID16020046 (1, 2.5 and 5 μM), cannabidiol (1 and 2.5 μM) or with MEK1/2 inhibitor PD184161 and ROCK inhibitors Y27632 and H-1152 for 1 h. Thereafter, a suspension of 1 × 10 5 cells was placed in the upper well; as a chemoattractant, 1% FBS in Opti-MEM ± 1 μM LPI was added into the bottom well. Cells were allowed to migrate for 17 h at 37°C and 5% CO 2 in a humidified incubator. Upon completion of migration, the upper sides of the filters were cleaned with a cotton swab, and filters were dried and fixed in formaldehyde for 30 min. After a wash in PBS, filters were mounted and coverslipped in Vectashield®. Cell nuclei were counted under a fluorescent microscope (Olympus IX 70). Each migration experiment was performed in duplicates.
The average number of migrated cells was determined from at least five independent experiments. type 8W10E+ was used to monitor the integrity of HUVEC cell monolayers at real-time in vitro. ECIS array wells were activated with L-cysteine (10 mM) and precoated with 1% gelatine for 30 min at 37°C. Then, wells were allowed to equilibrate with 200 μL HUVEC medium for 15 min at 37°C before HUVEC cells were added in additional 200 μL HUVEC medium to each well (1.5 × 10 5 cells per well). Monolayer formation was followed by impedance measurements. HUVEC cells were starved and challenged with monodisperse cell suspensions of HCT116 cells in fresh HUVEC starvation medium at a ratio of 1:1 (colon carcinoma vs. endothelial cells). Cancer cells were incubated with the appropriate concentrations of compounds in HUVEC starvation medium for 1 h before adding them to the well. The impedance of the challenged endothelial cell layer was monitored for 24 h.
Tracking of tumour cells in the liver of C57BL/6 mice
All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (McGrath et al., 2010) . Experimental procedures in mice were approved by the Austrian Federal Ministry of Science and Research (protocol number 66.010/0090/ÀII/ 3b/2012) and performed in accordance with national and international guidelines. Procedures were performed as humanely as possible to minimize all suffering. C57BL/6 (males, 5-9 weeks old, 20-26 g) were obtained from Charles River (Sulzfeld, Germany) and kept in house for 2 weeks before the experiments. Mice were housed in plastic sawdust floor cages at constant temperature (22°C) and a 12:12 h light-dark cycle with free access to standard laboratory chow and water. In total, 55 mice were used for the experiments. Tumour cell arrest in the liver was detected and quantified using a luciferase assay. HCT116 cells expressing a firefly luciferase (Luc-2) under the control of a cytomegalovirus (CMV) promoter (HCT116-CMVp-Luc) (Sack et al., 2011) were injected into the spleen at 1 × 10 6 cells in 50 μL volume under ketamine (100 mg·kg
À1
) and xylazine (10 mg·kg À1 ) anaesthesia. Heart rate was monitored during anaesthesia using the Physio Suite non-invasive monitoring system (Kent Scientific, Torrington, CT, USA). Three and a half hours after the injection, the left lobe of the liver was removed, rinsed in PBS, blotted and weighed and quickly transferred into lysis buffer [25 mM TRISphosphate (pH 7.8), 10% glycerol, 1% Triton-X-100, 1 mg·mL À1 BSA, 2 mM EGTA and 2 mM DTT]. After sonication and centrifugation, 100 μL of supernatant was added to assay reagent (reaction buffer, 1 mM luciferin, 2 mM ATP). Reaction buffer consisted of 25 mM glycylglycine, 15 mM MgSO 4 , 4 mM EDTA, 15 mM K 2 PO 4 (pH 7.8), 1 mM DTT and 1 mM CoA. After 1 min, luminescence was measured for 5 s at 562 nm at a TopCounter (Top Count NXT; Packard Instrument Company, Meriden, CT, USA). Luminescence values were normalized to liver wt and expressed as relative light units.
Human blood samples
Blood samples were provided as part of the OncoTrack project (http://www.oncotrack.eu/) by the General Hospital Graz West, St John of God Hospital Graz, Graz, Austria, and by the Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Austria. Blood was collected from colon cancer patients and healthy individuals (n = 7), drawn into heparin-containing plasma separation tubes (GreinerBio-One, Austria) and centrifuged within 2 h at 1600 x g for 10 min. Plasma was then transferred into cryotubes without disturbing the buffy coat layer. The specimens were stored at À80°C until use. Written informed consent was obtained from all patients. Ethical approval was granted by the ethics committee of the Medical University of Graz and confirmed by the ethics committee of the St John of God Hospital Graz (23-015 ex 10/11 and 17-291 ex 05/06).
LC-MS of LPI
Lipid extraction was carried out from 150 μL of sample in the presence of 10 μL of LPI 17:1 (100 μM) as internal standard according to Matyash et al. (2008) . LC-MS measurements for lipid quantification were performed with slight modifications as previously described in Fauland et al. (2011) . Briefly, chromatographic separation was performed on a Kinetex reversed-phase C18 2.1 × 150 mm (2.6 μm) column (Phenomenex, Torrance, USA). A LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) was used. The instrument was operated in preview mode for parallel MS/MS spectra in the linear ion trap, while running the Orbitrap in full scan mode at 100 000 resolution (m/z 400) from m/z 490 to 1100 in negative ESI-mode. Helium was used as the gas for linear ion trap collision-induced dissociation spectra. From the LTQ-FT preview scan, the three most abundant ions were selected in data-dependent acquisition, fragmented in the linear ion trap analyser and ejected at nominal mass resolution.
Statistical analysis
Data are presented as means ± SEM of at least n = 5 observations, unless stated otherwise. Statistical analyses were performed using one-way ANOVA followed by a Bonferroni's or Tukey's post hoc test and Student's t-test run on GraphPad Prism® software. P-values of <0.05 were considered significant.
Results
GPR55 contributes to adhesion of HCT116 colon cancer cells onto HUVEC cell monolayers. We first evaluated GPR55 expression in several different colon cancer cell lines by qPCR with highest expression observed in HCT116 cells ( Figure S1 ). HCT116 cells were pretreated for 1 h with either 1 or 2.5 μM ( Figure 1A ) of GPR55 antagonist CID16020046 (referred as CID in graphs) or cannabidiol respectively. The two compounds significantly diminished adhesion of HCT116 cells to a HUVEC cell monolayer at both concentrations used. At 2.5 μM of CID16020046, adhesion was diminished by more than 50%. Similar effects were observed using GPR55 siRNA ( Figure 1B) . The inhibitory effect of CID16020046 and cannabidiol on HCT116 cancer cell adhesion was absent when GPR55 expression was silenced with siRNA indicating a direct effect of CID16020046 and cannabidiol on GPR55 ( Figure 1C ). Knockdown of GPR55 in HCT116 cells, therefore, corroborated the results seen after the pharmacological inhibition of GPR55 activity. The siRNA knockdown of GPR55 resulted in a 50% loss of GPR55 mRNA levels ( Figure 1D ).
GPR55 is involved in the migration of HCT116 colon cancer cells. We then investigated the role of GPR55 in the migration of HCT116 cells towards a chemoattractant using agarose spot and Transwell migration assays (Figures 2 and 3 ). Ten percent FBS and 10% FBS + 2.5 μM LPI (agarose spot assay, Figure 2 ) and 1% FBS and 1% FBS + 1 μM LPI (Transwell migration assay, Figure 3 ) were used as chemotactic factors for HCT116 cells. Preincubation of HCT116 cells with 1 μM of CID16020046 or cannabidiol significantly reduced migration in both experimental settings (Figures 2A, B and 3A, B) . GPR55 knockdown significantly decreased GPR55-mediated HCT116 cell migration ( Figure 2C ). The inhibiting effect of CID16020046 and cannabidiol on HCT116 cancer cell migration was averted in cells following GPR55 knockdown, indicating a direct effect of CID16020046 and cannabidiol on GPR55 ( Figure 2D ). In line with another report (Ford et al., 2010) , LPI alone failed to significantly act as a chemoattractant for naïve HCT116 cells in the Transwell migration assay ( Figure 3E) ; however, it increased migration in GPR55 overexpressing HCT116 cells ( Figure 3F ). Incubation with 2.5 μM CID16020046 reversed the increase indicating that the inhibitor blocked LPI induced responses ( Figure 3G ). After incubation with 2.5 μM cannabidiol, the LPIinduced migratory response in GPR55 overexpressing HCT116 cells was decreased by around 50% ( Figure 3H ). LPI-induced formation of F-actin filaments (arrows in Figure 3I ) while preincubation with CID16020046 and cannabidiol inhibited that effect ( Figure 3I ). Representative pictures of migrated HCT116 cells from the spot and Transwell assay are shown in Figures 2E and 3J respectively. Preincubation with CID16020046 or cannabidiol over the length of the assays did not decrease cell viability ( Figure S2 ).
Blockade of GPR55 in HCT116 colon cancer cells changes the integrity of HUVEC cell monolayers. To study whether GPR55 could play a role in the passage of cancer cells through an endothelial barrier, another hallmark of cancer cell metastasis, we performed impedance-based assays (ECIS®) to examine whether co-culture with HCT116 cells can decrease the integrity of a HUVEC cell monolayer whereby a decrease in resistance correlates with a decrease in the monolayer's integrity (Figure 4 ). Co-culture of HCT116 cells with the HUVEC monolayer decreased resistance ( Figure 4A ), while pretreatment of HCT116 cells with 1 μM of CID16020046 or cannabidiol inhibited this decrease (seen as an increase of resistance compared with the DMSO control, Figure 4A ). Similar effects were observed with GPR55 knockdown cells ( Figure 4B ), while a loss of the monolayer integrity (seen as a decrease in resistance compared with untreated in HCT116 cancer cell adhesion and migration are ERK1/2 dependent. We used inhibitors of ERK1/2 and ROCK to investigate possible signalling pathways that participate in adhesion and migration of HCT116 cells. These two signalling molecules have been implicated in GPR55-mediated tumour growth and migration of neutrophils . The potent MEK1/2 inhibitor PD184161, which previously showed total inhibition of bicuculline-induced ERK1/2 phosphorylation at 5 μM in neuronal cell cultures (Gladbach et al., 2014) , blocked the ability of HCT116 cells to adhere by more than 50% ( Figure 5A ), while Y27632, a selective inhibitor of the Rho/ROCK pathway, failed to inhibit adhesion in naïve HCT116 cells ( Figure 5A ). In agarose spot ( Figure 5B ) and Transwell migration assays ( Figure 5C ), similar observations were made. Higher concentrations of PD184161 than 5 μM significantly reduced cell viability ( Figure S3 ) and were, therefore, not used in our experiments. Only in adhesion assays, which were evaluated after 1 h, 10 μM of PD184161 were used. No decrease in cell viability was detected at that time point (data not shown). Inhibition of the Rho/ROCK pathway using Y27632 significantly increased migration and adhesion of naïve HCT116 cells ( Figure 5B and C) .
In GPR55 overexpressing HCT116 cells, 5 μM of PD184161 blocked the LPI-induced migratory response in the Transwell migration assay ( Figure 5D ). Similar to ROCK inhibitor Y2763, a different ROCK inhibitor, H-1152, was unable to significantly decrease the LPI-induced migratory response in the Transwell assay at 10 nM ( Figure S3A ) and had no effect in the adhesion assay using naïve HCT116 cells ( Figure S3B ).
GPR55 is involved in the arrest of HCT116 colon cancer cells in the liver after intrasplenic inoculation. To examine whether GPR55 might also play an important role in migration and invasion, we used a model of liver metastasis and injected HCT116 cells that expressed a firefly luciferase (Luc-2) under the control of a CMV promotor (HCT116-CMVpLuc) (Sack et al., 2011) intrasplenically into mice. GPR55 expression was detected in HCT116-CMVp-Luc cells comparable with HCT116 cells ( Figure S4 ). In order to quantify arrested cancer cells, liver tissue was evaluated for luciferase activity 3.5 h after injection of cells (1 × 10 6 cells in 50 μL; Sack et al., 2011) . To visually demonstrate the actual arrest of HCT116-CMVp-Luc cells in the liver, cells were transfected with GFP and visualized by fluorescence microscopy in liver sections 3.5 h after intrasplenic inoculation ( Figure 6D ). No cells with a passage number higher than seven were used for these experiments. In vivo treatment (i.p.) with 10 mg·kg À1 CID16020046 or with 5 mg·kg À1 cannabidiol led to a significant reduction in arrest of intrasplenically injected HCT116-CMVp-Luc cells, as evaluated by luciferase activity in the liver ( Figure 6A and B). Preincubation of HCT116-CMVp-Luc cells only with CID16020046 (1 and 2.5 μM) 1 h prior to their intrasplenic injection concentration-dependently inhibited luciferase activity in the liver ( Figure 6C ). LPI content in human plasma. Mass spectrometry data revealed that, in particular, LPI (18:0) was increased in plasma samples of colon cancer patients when compared with healthy controls (Figure 6E ), while total LPI (16:0, 18:0, 24:0) only tended to be increased (probably due to the low sample size,~40% power) ( Figure 6F ).
Discussion and conclusion
GPCRs activated by lysophospholipid ligands, for example lysophosphatidic acid (LPA) receptors, are regarded as important players in the development of cancer (Dorsam and Gutkind, 2007) . This raises the possibility that other lysophospholipid ligand-responsive GPCRs like GPR55 could exert protumorigenic behaviour in a similar way. In parallel, high levels of endogenous ligands of these GPCRs may add to carcinogenesis. For instance, LPI, the endogenous GPR55 ligand, has been reported to be elevated in the blood of patients with ovarian cancer (Shen et al., 2001) . The pathophysiological function of the GPR55-LPI axis has, therefore, gained increasing attention as a potential driving force in cancer (Ross, 2011) . In our present study, we demonstrated that the GPR55-LPI axis plays an important role in the metastatic behaviour of colon cancer cells in vitro and in vivo.
One of the main features of metastasis is the adherence of cancer cells to the endothelial lining and the colonization of secondary organs (Hanahan and Weinberg, 2011) . By use of the recently characterized selective GPR55 antagonist CID16020046 (Kargl et al., 2013a; Kotsikorou et al., 2013) and through GPR55 siRNA knockdown, we show that adherence of HCT116 colon cancer cells to endothelial cells was significantly inhibited. The GPR55 antagonist also inhibited invasion and migration of the cancer cells in the chemotactic assays. These data clearly indicate a crucial role for GPR55 in colon cancer cell migration and for LPI in the integrity of the endothelial barrier challenged by HCT116 cells. It is not Figure 5 Adhesion and migration of HCT116 cancer cell are ERK1/2 dependent. Adhesion (A) and migration assays (B-D) were performed using naïve and GPR55 overexpressing HCT116 cells. Naïve HCT116 cells were either pretreated with ERK1/2 inhibitor PD184161 (5 μM) or ROCK inhibitor Y27632 (25 and 50 μM) for 1 h and (A) adhesion (n = 5-6), (B) agarose spot (n = 3) and (C) Transwell migration assays (n = 6-8) were performed. PD184161 significantly diminished HCT116 cell adhesion to HUVEC cell monolayer and significantly reduced cell migration, while Y27632 increased the effects. (D) In GPR55 overexpressing HCT116 cells, 5 μM of PD184161 blocked the LPI-induced responses in the Transwell migration assay. ANOVA with Bonferroni's post hoc test. * P < 0.05; ** P < 0.01; *** P < 0.001. into C57BL/6 mice to visually demonstrate arrested cancer cells in the liver. The left liver lobe was frozen on dry ice; sections were cut on a cryostat and mounted on slides. Images were taken under a fluorescent microscope (Olympus IX 70) with a Hamamatsu ORCA CCD camera and xcellence® Olympus imaging software (Olympus, Vienna, Austria). Transient pcDNA-EGFP plasmid transfection was performed using Lipofectamine 2000 following the manufacturer's instructions (Life Technologies). (E, F) The endogenous ligand of GPR55, LPI, was evaluated by LC-MS in blood samples of colon cancer patients and healthy individuals (control); n = 7; Student's t-test. * P < 0.05; ** P < 0.01. LPI (18:0) showed significant increases in colon cancer patients in comparison with healthy subjects, while total LPI (16:0, 18:0, 24:0) showed a slight but non-significant increase compared with controls. CV, central vein; RLU, relative light units.
clear, how LPI-treated HCT116 cells alter the endothelial integrity. However, it should be noted that LPI is an inducer of nuclear factor of activated T-cells (NFAT; Henstridge et al., 2009) , which has been implicated in cancer cell migration (Mancini and Toker, 2009) . One of the genes transactivated by NFAT encodes for autotaxin, which produces LPA, a potent mitogen in breast cancer (rev. in Mancini and Toker, 2009 ). LPA has been also shown to strongly enhance endothelial permeability (van Nieuw Amerongen et al., 2000) , which may have been the case in our experimental set-up. An activated LPI-GPR55 axis is likely present in colon cancer patients who show increased blood levels of LPI as observed in our study. High levels of LPI could easily influence interaction of cancer cells with endothelia because it is not only produced in endothelial and cancer cells (Martin and Wysolmerski, 1987; Piñeiro et al., 2011) but also in neutrophils (Smith and Waite, 1992) and platelets (Billah and Lapetina, 1982) , that is, in cells that assist invading tumour cells (Hanahan and Weinberg, 2011) . We also investigated the effects of cannabidiol, a nonpsychoactive natural cannabinoid, on adhesion and migration of HCT116 colon cancer cells and whether cannabidiol effects could be mediated by GPR55. It has been previously reported that migration and invasion of cancer cells are inhibited by cannabidiol (Vaccani et al., 2005; Ramer et al., 2012) . In events like these, cannabidiol could act as an antagonist at GPR55 (Ryberg et al., 2007; Anavi-Goffer et al., 2012; Kotsikorou et al., 2013) ; however, cannabidiol has been also described as a ligand of other receptors, such as TRPV2, PPARγ and 5-HT 1A receptors (Izzo et al., 2009) . In particular, TRPV2, a non-selective cation channel with Ca 2+ permeability, can be activated by cannabidiol in cancer cells (Nabissi et al., 2013) . This could have changed Ca 2+ homeostasis in the HCT116 cells and influenced migration and adhesion (Prevarskaya et al., 2011) . Nevertheless, in our assays, inhibition of adhesion/migration by cannabidiol was clearly diminished by GPR55 siRNA knockdown indicating a major role of the GPR55 receptor in the anti-migratory and anti-adhesion effects of cannabidiol. Oncogenic properties of GPR55 in cancer cells involve ERK1/2 activity and Ca 2+ signalling Piñeiro et al., 2011) . In a recent work, we were able to show that the GPR55 antagonist CID16020046 inhibited LPIinduced responses in GPR55-HEK293 cells, such as Ca 2+ flux and ERK1/2 activity (Kargl et al., 2013a) . We were, therefore, interested whether the process of adhesion and migration may include these typical GPR55-activated pathways. Blockade of ERK1/2, but not of ROCK, inhibited adhesion and migration of HCT116 cells on endothelial cells indicating that the ERK1/2 pathway may not only be important for GPR55-mediated proliferation of cancer cells but also for cancer cell adhesion to and migration through the endothelium. For all our assays, we used the highly selective MEK1/2 inhibitor PD184161, which is structurally almost identical to PD184352, a MEK inhibitor with no known inhibition of other protein kinases (up to 10 μM) and a selectivity superior to U0126 (Davies et al., 2000) . Interestingly, the ROCK inhibitor Y27632 increased adhesion and migration of HCT116 cells, a finding also observed by others Adachi et al., 2011) . Another ROCK inhibitor, H-1152, was also ineffective in inhibiting migration and adhesion suggesting that alternative or additional signalling pathways to Rho/ROCK exist in the migration of colon cancer cells.
To explore the relevance of the GPR55-LPI axis in colon cancer patients, we evaluated LPI content in the blood of colon cancer patients in comparison with healthy individuals. We detected significantly increased LPI (18:0) content in plasma from colon cancer patients possibly indicating an activated LPI-GPR55 axis. In a previous study, stearic (18:0) acid has been shown to constitute one of the major fatty acid components of LPI in serum of healthy individuals and patients with ovarian cancer (Shen et al., 2001) , which may be a reason why we measured significant differences only for the LPI (18:0) species and not for total LPI between colon cancer patients and healthy subjects. Piñeiro et al. (2011) cancer cells by LPI also correlated with increased migration (Monet et al., 2009 ) and proliferation (Piñeiro et al., 2011) , an involvement of LPI in growth and metastasis of colon cancer cells is quite conceivable. LPI was also reported to enhance migration of the metastatic breast cancer cell line MDA-MB-231, which expresses high levels of GPR55 (Ford et al., 2010) . In accordance with that study, we could also show that GPR55 overexpression in HCT116 cells enhanced the GPR55 antagonist-sensitive migratory response to LPI. Thus -next to ovarian cancer -colon cancer patients reveal increased LPI levels suggesting LPI as an interesting biomarker candidate for colon cancer. We finally employed a mouse model and investigated in vivo whether GPR55 may alter adhesion and migratory behaviour of colon cancer cells in organs that are first colonized by colon tumour cells. Treatment of mice with the GPR55 inhibitor or cannabidiol diminished the arrest of HCT116-CMVp-Luc cells in the liver as evaluated by luciferase activity. The GPR55 antagonists, therefore, slowed down metastasis of liver tissue with colon cancer cells. When only HCT116-CMVp-Luc cells were pretreated with CID16020046 before injection, this had the same inhibitory effect, which proved that GRR55 expressed on the cancer cells rather than endothelial cells were mediating the metastatic effect.
To summarize, in the present study, we demonstrated that GPR55 is involved in metastatic behaviour of colon cancer cells such as adhesion, invasion and migration and in the arrest of colon cancer cells in liver tissue. These properties were blocked by GPR55 antagonism. Together with the increase of LPI levels in colon cancer patients and the presence of GPR55 in colon tumour cells, it is suggested that the LPI-GPR55 axis could be involved in the metastasis of colon cancer cells. In light of the limited therapeutic options to interfere with metastasis of colon cancer, further studies are needed to reveal insight into GPR55-mediated mechanisms of metastasis. and P22771 to R. S. and P22521-B18 to A. H.), the Austrian National Bank (OeNB 14429 to R. S. and 14263 to A. H.) and the Innovative Medicines Initiative Joint Undertaking (IMI) grant (grant agreement no. 115234, OncoTrack to J. H.). J. K. is funded by the PhD and the START Funding programme of the Medical University of Graz.
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http://dx.doi.org/10.1111/bph.13345 Figure S1 HCT116 colon cancer cells express GPR55 mRNA. GPR55 expression was evaluated in several colon cancer cell lines (HT29, SW480, HCT116; all from Interlab Cell Line Collection, Genoa, Italy). Compared to two other colon cancer cell lines (SW480 and HT29), qPCR showed that HCT116 expressed the highest copy numbers of GPR55. We therefore decided to continue with HCT116 cells for all the following experiments. Figure S2 Viability of HCT116 cells was measured after 17 hrs upon treatment with increasing concentrations of cannabidiol (CBD), GPR55 antagonist CID16020046 (CID) and PD184161 using the MTS assay (Cell Titer 96® AQueous One Solution Cell Proliferation Assay). Absorbance was measured at 490 nm after incubating the cells with MTS substrate for 60-100 min and afterwards normalized to vehicle. At the indicated concentrations, CID and cannabidiol did not influence cell viability. Higher concentrations of PD184161 (10 μM) significantly reduced cell viability. Data are means ± SEM from at least 4 independent experiments performed in triplicates. ANOVA; Tukey's post-hoc test. Figure S3 (A) Incubation with ROCK inhibitor H-1152 (10 nM) had no significant effect on the migration of LPI induced migratory responses of GPR55 overexpressing HCT116 in the Transwell migration assay (veh, vehicle = DMSO; n = 6-8; one-way ANOVA; Tukey's post hoc test). (B) Incubation with Rock inhibitor H-1152 (10 nM) had no effect on the adhesion of naïve HCT116 cells onto a HUVEC cell monolayer (n = 6; t-test; n.s., not significant). Figure S4 PCR amplification of GPR55 transcripts. Gel showing bands of amplicons of passages 4 (p4) and 7 (p7) from HCT116 cancer cells and passage 6 (p6) of HCT116-CMVp-Luc cancer cells (HCT116-Luc). HCT116 as well as HCT116-CMVp-Luc cancer cells express GPR55 transcripts. Amplicons were electrophoresed in 1% agarose gel and stained with ethidiumbromide. GPR55 pcDNA3.1 plasmid (10 ng; Kargl et al., 2012) was used as positive control.
